why choose us

First received: April 07, 2023

Clinical Trial: Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell L

Study Type: INTERVENTIONAL


Official Title: A Phase II Trial of Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Brief Summary: This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refractory).Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.Lenalidomide may have antineoplastic activity which may help block the formation of growths that may…

Read more